601 related articles for article (PubMed ID: 27532886)
1. Therapy-Emergent Drug Resistance to Integrase Strand Transfer Inhibitors in HIV-1 Patients: A Subgroup Meta-Analysis of Clinical Trials.
You J; Wang H; Huang X; Qin Z; Deng Z; Luo J; Wang B; Li M
PLoS One; 2016; 11(8):e0160087. PubMed ID: 27532886
[TBL] [Abstract][Full Text] [Related]
2. Effects of raltegravir or elvitegravir resistance signature mutations on the barrier to dolutegravir resistance in vitro.
Seki T; Suyama-Kagitani A; Kawauchi-Miki S; Miki S; Wakasa-Morimoto C; Akihisa E; Nakahara K; Kobayashi M; Underwood MR; Sato A; Fujiwara T; Yoshinaga T
Antimicrob Agents Chemother; 2015 May; 59(5):2596-606. PubMed ID: 25691633
[TBL] [Abstract][Full Text] [Related]
3. The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance.
Liang J; Mesplède T; Oliveira M; Anstett K; Wainberg MA
J Virol; 2015 Nov; 89(22):11269-74. PubMed ID: 26311878
[TBL] [Abstract][Full Text] [Related]
4. Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity.
Anstett K; Fusco R; Cutillas V; Mesplède T; Wainberg MA
J Virol; 2015 Oct; 89(20):10482-8. PubMed ID: 26246578
[TBL] [Abstract][Full Text] [Related]
5. Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir.
Oliveira M; Ibanescu RI; Anstett K; Mésplède T; Routy JP; Robbins MA; Brenner BG;
Retrovirology; 2018 Aug; 15(1):56. PubMed ID: 30119633
[TBL] [Abstract][Full Text] [Related]
6. Durable suppression of HIV-1 with resistance mutations to integrase inhibitors by dolutegravir following drug washout.
Osman N; Mesplède T; Oliveira M; Hassounah S; Wainberg MA; Brenner BG
AIDS; 2018 Aug; 32(13):1773-1780. PubMed ID: 29894388
[TBL] [Abstract][Full Text] [Related]
7. Meta-analysis and systematic review of the efficacy and resistance for human immunodeficiency virus type 1 integrase strand transfer inhibitors.
Yang LL; Li Q; Zhou LB; Chen SQ
Int J Antimicrob Agents; 2019 Nov; 54(5):547-555. PubMed ID: 31398480
[TBL] [Abstract][Full Text] [Related]
8. Susceptibility to HIV-1 integrase strand transfer inhibitors (INSTIs) in highly treatment-experienced patients who failed an INSTI-based regimen.
Santoro MM; Fornabaio C; Malena M; Galli L; Poli A; Menozzi M; Zazzi M; White KL; Castagna A;
Int J Antimicrob Agents; 2020 Jul; 56(1):106027. PubMed ID: 32450199
[TBL] [Abstract][Full Text] [Related]
9. Comparable
Saladini F; Giannini A; Boccuto A; Dragoni F; Appendino A; Albanesi E; Vicenti I; Zazzi M
Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31611362
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 integrase strand transfer inhibitors: a review of current drugs, recent advances and drug resistance.
Mbhele N; Chimukangara B; Gordon M
Int J Antimicrob Agents; 2021 May; 57(5):106343. PubMed ID: 33852932
[TBL] [Abstract][Full Text] [Related]
11. Differences among HIV-1 subtypes in drug resistance against integrase inhibitors.
Han YS; Mesplède T; Wainberg MA
Infect Genet Evol; 2016 Dec; 46():286-291. PubMed ID: 27353185
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the Drug Resistance Profiles of Integrase Strand Transfer Inhibitors in Simian Immunodeficiency Virus SIVmac239.
Hassounah SA; Liu Y; Quashie PK; Oliveira M; Moisi D; Brenner BG; Sandstrom PA; Mesplède T; Wainberg MA
J Virol; 2015 Dec; 89(23):12002-13. PubMed ID: 26378179
[TBL] [Abstract][Full Text] [Related]
13. Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile.
Tsiang M; Jones GS; Goldsmith J; Mulato A; Hansen D; Kan E; Tsai L; Bam RA; Stepan G; Stray KM; Niedziela-Majka A; Yant SR; Yu H; Kukolj G; Cihlar T; Lazerwith SE; White KL; Jin H
Antimicrob Agents Chemother; 2016 Dec; 60(12):7086-7097. PubMed ID: 27645238
[TBL] [Abstract][Full Text] [Related]
14. Effect of HIV-1 integrase resistance mutations when introduced into SIVmac239 on susceptibility to integrase strand transfer inhibitors.
Hassounah SA; Mesplède T; Quashie PK; Oliveira M; Sandstrom PA; Wainberg MA
J Virol; 2014 Sep; 88(17):9683-92. PubMed ID: 24920794
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort.
Modica S; Rossetti B; Lombardi F; Lagi F; Maffeo M; D'Autilia R; Pecorari M; Vicenti I; Bruzzone B; Magnani G; Paolucci S; Francisci D; Penco G; Sacchini D; Zazzi M; De Luca A; Di Biagio A
HIV Med; 2019 Feb; 20(2):137-146. PubMed ID: 30461149
[TBL] [Abstract][Full Text] [Related]
16. HIV-1 Group O Resistance Against Integrase Inhibitors.
Depatureaux A; Mesplède T; Quashie P; Oliveira M; Moisi D; Plantier JC; Brenner B; Wainberg MA
J Acquir Immune Defic Syndr; 2015 Sep; 70(1):9-15. PubMed ID: 26017662
[TBL] [Abstract][Full Text] [Related]
17. Resistance mutations outside the integrase coding region have an effect on human immunodeficiency virus replicative fitness but do not affect its susceptibility to integrase strand transfer inhibitors.
Weber J; Rose JD; Vazquez AC; Winner D; Margot N; McColl DJ; Miller MD; Quiñones-Mateu ME
PLoS One; 2013; 8(6):e65631. PubMed ID: 23776513
[TBL] [Abstract][Full Text] [Related]
18. Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients.
Fourati S; Charpentier C; Amiel C; Morand-Joubert L; Reigadas S; Trabaud MA; Delaugerre C; Nicot F; Rodallec A; Maillard A; Mirand A; Jeulin H; Montès B; Barin F; Bettinger D; Le Guillou-Guillemette H; Vallet S; Signori-Schmuck A; Descamps D; Calvez V; Flandre P; Marcelin AG;
J Antimicrob Chemother; 2015 May; 70(5):1507-12. PubMed ID: 25558077
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 Integrase Inhibitors That Are Active against Drug-Resistant Integrase Mutants.
Smith SJ; Zhao XZ; Passos DO; Lyumkis D; Burke TR; Hughes SH
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32601157
[TBL] [Abstract][Full Text] [Related]
20. Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness.
Abram ME; Hluhanich RM; Goodman DD; Andreatta KN; Margot NA; Ye L; Niedziela-Majka A; Barnes TL; Novikov N; Chen X; Svarovskaia ES; McColl DJ; White KL; Miller MD
Antimicrob Agents Chemother; 2013 Jun; 57(6):2654-63. PubMed ID: 23529738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]